The Mayo Clinic has partnered with Thermo Fisher Scientific to launch a new group focused on reaping large-scale data that could lead to the understanding and development of new treatments, devices and diagnostics.
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new drug (IND) application process that the agency hopes will put U.S. phase 1 trials on par with those in China and Australia.
Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s AFib device Laminar program for an undisclosed price.
Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.
Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched cystic fibrosis add-on program.
Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.
The FDA has signed off on the first ever glioma drug imaging diagnostic more than a year after it initially rejected the med.
GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The deal comes two years after GSK paid China’s Chimagen $300 million upfront for a trispecific lupus prospect.
Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two years.
A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.
Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis has missed its primary endpoint.
AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.
As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously studied in the real world.
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug ipsoprubart.
Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The biotech plans to enter phase 2.
Is the cancer truly gone?
The future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.
Johnson & Johnson is nearing a $20 billion deal to sell off its unwanted hips-and-knees business DePuy Synthes to private equity firm Apollo Equity Management.
As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.